An analysis of available data on changes in office or out-of-office BP during treatment with SGLT-2 inhibitors made by Kario et al. evidenced consistent reductions in home, 24 h, daytime, and nocturnal BP during treatment with SGLT-2 inhibitors in patients with diabetes and hypertension; patient subgroups with a higher BMI and higher baseline BP had greater reductions in BP during treatment with SGLT-2 inhibitors [67,68]. The gene discussed is SLC5A2; the disease is diabetes mellitus.